What did Vasella see in Alcon?

Just why would Novartis pay $11 billion for one-fourth of an eye-care company and promise another $28 billion for another big chunk? The Wall Street Journal asked CEO Daniel Vasella (photo) just that. You've heard some of the reasons Novartis wanted Alcon: aging population, meaning more people with eye-care needs; and diversification. Here's another: The lack of pricing pressure on eye products. While insurers and government healthcare systems are twisting drugmakers' arms for pharma discounts, consumers typically are paying for the kind of eye-care products Alcon sells. "You can pass on price increases easier," Vasella said. "As soon as you get into regulated markets like pharma, it's more difficult."

And there lies the rub for much of the drug industry right now. Vasella predicts that pharma prices on the whole will decline--unless and until R&D innovation declines. "[T]hen society will have to make a decision: Do we want innovation or not?" he says.

- find more from Vasella in the WSJ
- check out an excerpt from that interview at Pharmalot

Related Articles:
Novartis: No more deals, no Roche sale.
Novartis pledges $39B for Alcon
Alcon faces setback on experimental AMD therapy
Cash-rich Novartis CEO mulls biotech buyouts
CEO: Novartis plans big restructuring

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.